We can’t show the full text here under this license. Use the link below to read it at the source.
Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
Balancing Risks and Benefits of Two Diabetes Drug Types in Type 2 Diabetes: Review and Analysis
AI simplified
Abstract
In a meta-analysis of 17 cardiovascular outcome trials involving 132,038 participants, both GLP-1 receptor agonists and SGLT-2 inhibitors reduced .
- Both GLP-1 receptor agonists and SGLT-2 inhibitors demonstrated a reduction in major adverse cardiovascular events with hazard ratios of 0.87.
- SGLT-2 inhibitors were superior to GLP-1 receptor agonists in reducing and renal outcomes.
- GLP-1 receptor agonists were associated with an increased risk of retinopathy, while SGLT-2 inhibitors were linked to a higher incidence of genitourinary infections and diabetic ketoacidosis.
- Net benefits favored GLP-1 receptor agonists for major adverse cardiovascular events, while SGLT-2 inhibitors showed marginal net benefits depending on the harms considered.
- The certainty of evidence was rated high for efficacy outcomes and moderate for safety concerns.
AI simplified
Key numbers
HR 0.87
Reduction with GLP-1RAs
Pooled hazard ratio for across trials.
HR 0.69
Heart Failure Hospitalization with SGLT-2is
Pooled hazard ratio for .
+2.5/1000
Net Benefit of GLP-1RAs for
Net benefit per 1000 treated patients.